FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to medicine and pharmacy. Disclosed is use of isopropyl β-(3,4-dihydroxyphenyl)-α-hydroxypropionate (IDHP) for thrombocyte aggregation inhibition and use of IDHP to stimulate angiogenesis. Inventions can become a basis for using IDHP in developing agents for thrombocyte aggregation and for stimulating angiogenesis.
EFFECT: technical result consists in implementation of declared applications.
2 cl, 8 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 4-FLUORO-N-INDANE-2-YLBENZAMIDE AND ITS USING AS PHARMACEUTICAL AGENT | 2002 |
|
RU2308946C2 |
| USE OF FLAVONOLIGNANS FOR INHIBITION OF EXCESSIVE AND PATHOLOGICAL PROLIFERATION OF VESSEL ENDOTHELIUM | 2005 |
|
RU2291706C1 |
| TREATING OCULAR DISEASES | 2007 |
|
RU2472523C2 |
| PHARMACEUTICAL PREPARATION FOR TREATING BENIGN PROSTATIC HYPERPLASIA | 2008 |
|
RU2485971C2 |
| METHOD OF ESTIMATING ANGIOGENIC POTENTIAL OF PROGENOTOR CELLS IN PATIENTS WITH CARDIOVASCULAR DISEASES | 2011 |
|
RU2548801C2 |
| APPLICATION o-ATF FOR TREATMENT OF DISEASES INCLUDING ANGIOGENESIS | 2005 |
|
RU2359679C2 |
| HUMAN PROTEIN TYROSINE PHOSPHATASE BETA BINDING ANTIBODIES (HPTPBETA), AND USE THEREOF | 2007 |
|
RU2494108C2 |
| REGULATOR OF NEUTROPHIL ACTIVATION | 2018 |
|
RU2742417C1 |
| MITOCHONDRIAL DNA LESIONS BEING THE SIGN OF ATHEROSCLEROTIC ISCHEMIC CARDIAC DISEASE | 2000 |
|
RU2243558C2 |
| ANGIOGENESIS PROMOTING AGENT AND METHODS FOR ITS USE | 2018 |
|
RU2771982C2 |
